Opioid analgesics are largely implemented for the relief of acute pain in several clinical
settings, including among patients with acute coronary syndrome (ACS) undergoing …

Aims Opioid analgesia has been shown to interfere with the bioavailability of oral P2Y12
inhibitors prompting the search for safe and effective non-opioid analgesics to treat …

Background There is increasing evidence that opioids interfere with the oral bioavailability of
P2Y 12 inhibitors leading to delayed onset of antiplatelet effects. Several strategies have …

Morphine has been long recognized as standard of care in the treatment of acute coronary
syndrome (ACS) patients; however, its safety has recently been called into question due to a …

Key Points Opioid therapy has served as the cornerstone for pain relief in acute coronary
syndromes (ACS) for several decades. Women with ACS are less likely to receive opioids for …

As recommended in the European Society of Cardiology guidelines, titrated intravenous
opioids should be considered to relieve pain in patients presenting with ST-segment …

Background Opioid analgesia impairs the bioavailability and antiplatelet effect of oral P2Y12
inhibitors prompting investigation of mitigation strategies including identifying alternative …

Graphical Abstract Advantages and disadvantages of opioid and non-opioids analgesics in
patients undergoing percutaneous coronary interventions. Among patients undergoing …

In this issue of Thrombosis and Haemostasis, Ibrahim et al from Johns Hopkins University
School of Medicine, Baltimore, Maryland, United States, add important findings to the …

Antiplatelet treatment is a cornerstone in the treatment of patients with acute coronary
syndrome (ACS). Still, all patients are unique and we need to present a tailor-made …